Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.8.0.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Mar. 31, 2018
Mar. 31, 2017
Revenues $ 78 $ 37 $ 353 $ 247
Operating expenses:        
Research and development (related party of $227, $225, $600 and $670), net of grant income of $0, $44, $44 and $84 966 1,136 2,944 3,005
General and administrative (related party of $186, $191, $573 and $533) 2,605 2,837 7,690 7,657
Total operating expenses 3,571 3,973 10,634 10,662
Operating loss (3,493) (3,936) (10,281) (10,415)
Other income (expense):        
Interest expense (related party of $478, $481, $1,437 and $1,447) (478) (481) (1,437) (1,447)
Interest income 4 8 13 33
Royalty income 4 4 15 20
Total other income (expense) (470) (469) (1,409) (1,394)
Consolidated net loss (3,963) (4,405) (11,690) (11,809)
Net loss attributable to noncontrolling interest 1 492 3 1,606
Net loss attributable to iBio, Inc. (3,962) (3,913) (11,687) (10,203)
Preferred stock dividends (64) (26) (195) (26)
Net loss available to iBio, Inc. $ (4,026) $ (3,939) $ (11,882) $ (10,229)
Comprehensive loss:        
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted $ (0.03) $ (0.04) $ (0.12) $ (0.11)
Weighted-average common shares outstanding - basic and diluted 115,449 89,109 102,473 89,109